COMMUNIQUÉS West-GlobeNewswire

Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
13/07/2026
Appointments bring global oncology drug development experience and deepen Board’s operational and regulatory expertise SOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: [...]
Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists
13/07/2026
SINGAPORE and NORTH BRUNSWICK, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative [...]
Picard Medical / SynCardia Releases Annual Stockholder Presentation Ahead of 2026 Annual Meeting
13/07/2026
Presentation Highlights Business Progress, Product Development Milestones, and Matters for Stockholder Consideration TUCSON, Ariz., July 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) ("Picard [...]
Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
13/07/2026
Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a [...]
Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy
13/07/2026
Expands potential benefit for treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancer Findings suggest broader utility in cancer supportive care, building on interim [...]
Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit
13/07/2026
PURCHASE, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and [...]
Fortrea Announces Date for Second Quarter 2026 Financial Results and Conference Call
13/07/2026
DURHAM, N.C., July 13, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its second quarter 2026 financial [...]
Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026
13/07/2026
- Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to [...]
REPEAT - Grifols deaths and harm: Patient safety & options for accountability
13/07/2026
TORONTO, July 13, 2026 (GLOBE NEWSWIRE) -- Will Trial Lawyers and the Ontario Health Coalition invite members of the media to attend a press conference regarding patient safety issues related to Grifols, one of the [...]
Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®
13/07/2026
New agreement, effective January 1, 2027, to add approximately 9 million Medicare lives (16% of approximately 55 million Medicare lives in the U.S.) On top of two previously announced major commercial payer agreements [...]
Apollomics Regains Full Compliance with Nasdaq Listing Requirements
13/07/2026
FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to [...]
Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial
13/07/2026
Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers Company to hold Type D meeting with FDA to discuss a potential registrational [...]
Acentra Health Appoints Michael Kingston as Chief Digital & Information Officer to Lead Technology and AI Innovation
13/07/2026
New executive leadership role to accelerate innovation, modernize technology, and advance the company's long-term growth strategy MCLEAN, Va., July 13, 2026 (GLOBE NEWSWIRE) -- Acentra Health , a technology and health [...]
Solésence Brings Patent-Backed Skin Health Innovation to Hair and Scalp
13/07/2026
New White Label Collection, Powered by WHSPR™ and Kleair™, Debuts with Revitalizing Scalp Serum and Scalp Screen Dry Shampoo SPF 45+ Sunscreen Scalp Screen Dry Shampoo SPF 45+ Sunscreen Named a Finalist for the 2026 [...]
Bexorg Expands Leadership Team with Appointments of Bruce Car, Ph.D., as Chief Scientific Officer and Michael Fenn, Ph.D., as Chief Business Officer
13/07/2026
- Dr. Car brings more than 30 years of drug discovery experience to lead Bexorg's next phase of clinical translation; Dr. Fenn joins Bexorg to lead business development, asset strategy, and corporate development - [...]
FDA Grants De Novo Classification to Claria Medical for Device Designed to Improve Safety and Efficiency of Hysterectomy Procedures
13/07/2026
Claria System is the first integrated tissue containment and removal system authorized by the FDA, granted through its Safer Technologies Program for its potential impact on women’s health MOUNTAIN VIEW, Calif., July 13 [...]
New Phase 1 Data Show VNA-318 Mechanism of Action Translates to Humans, Supporting Potential to Address Medical Needs of People with Neurodegenerative Diseases
13/07/2026
Pharmacodynamic effects in the human brain and energy metabolism biomarker data presented at AAIC support further clinical development of VNA-318 in Alzheimer’s disease LAUSANNE, Switzerland, July 13, 2026 – Vandria, a [...]
ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis
13/07/2026
Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline CST with statistical significance at 6 months The most common adverse events reported were consistent [...]
Santhera Expands Biomedica Agreement to Extend AGAMREE® (Vamorolone) Distribution Across Central Asia and the Caucasus
13/07/2026
Pratteln, Switzerland, July 13, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announces an expansion of its exclusive distribution agreement with Biomedica for AGAMREE® (vamorolone), extending the partnership to [...]

Pages